Innovative Cellular Therapeutics Holdings Ltd 4

What Happened

• Innovative Cellular Therapeutics Holdings Ltd, a 10% owner of Lyell Immunopharma, transferred 66,500 shares of Lyell common stock on 2026-06-15. The shares were transferred for no cash consideration (reported at $0.00) as a broker commission in connection with an upfront payment under a license agreement. This disposition is reported under Form 4 transaction code J (other acquisition/disposition). After the transfer, the reporting entity directly holds 2,933,500 shares (down from 3,000,000).

Key Details

• Transaction date: 2026-06-15; Filing date: 2026-06-18 (filed three days after the transaction; this may be later than the usual 2-business-day Form 4 deadline).
• Shares transferred: 66,500; reported price: $0.00; reported total value: $0 (transfer for no cash consideration).
• Shares owned after the transaction: 2,933,500 (held directly, registered in the reporting person’s name).
• Footnote: The transfer was to LifeSci Advisors, LLC as broker commission related to the Upfront Payment under the License Agreement dated Nov 6, 2025; reported under transaction code J.
• Insider type: 10% owner (institutional holder), not an executive officer or director.

Context

• Transfers of shares as broker commissions are administrative/disposition events and do not necessarily reflect the owner’s view of the stock. Because this was a non-cash transfer to pay a broker commission tied to a contractual upfront payment, it differs from an open-market sale. Retail investors should note the change in outstanding insider holdings (a modest reduction) but avoid reading this as a straightforward buy/sell signal.